Related Experiment Videos
Hepatitis B and liver transplantation.
1Division of Gastroenterology, University of Washington School of Medicine, Seattle, WA 98195, USA.
Summary
Liver transplantation for chronic hepatitis B is effective but risks viral recurrence. Antivirals and immune globulin improve outcomes, yet high costs and drug resistance remain challenges for preventing hepatitis B virus infection.
Area of Science:
- Hepatology
- Transplant Surgery
- Virology
Background:
- Liver transplantation is the primary treatment for end-stage liver disease due to chronic hepatitis B.
- Recurrent hepatitis B virus (HBV) infection post-transplant significantly reduces graft and patient survival.
- High HBV viral load at transplantation is a key predictor of recurrence.
Purpose of the Study:
- To review current strategies for preventing recurrent hepatitis B virus infection after liver transplantation.
- To highlight the challenges associated with existing prophylactic regimens.
- To emphasize the need for cost-effective and mutation-resistant approaches.
Main Methods:
- Review of existing literature on hepatitis B virus recurrence post-liver transplantation.
- Analysis of the efficacy and limitations of antiviral medications (e.g., lamivudine, adefovir).
- Evaluation of prophylactic regimens involving hepatitis B immune globulin.
Main Results:
- Antiviral therapies and hepatitis B immune globulin have improved post-transplant outcomes.
- High treatment costs and the emergence of drug-resistant HBV mutations are significant barriers.
- Viral load at the time of transplantation remains a critical risk factor.
Conclusions:
- Despite advancements, preventing recurrent hepatitis B virus infection after liver transplantation requires further research.
- Developing cost-effective strategies and addressing drug resistance are crucial for long-term success.
- Optimizing prophylaxis is essential to improve survival rates in liver transplant recipients.